Adaptive Biotechnologies
ADPT
226 hedge funds and large institutions have $1.18B invested in Adaptive Biotechnologies in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 85 increasing their positions, 63 reducing their positions, and 22 closing their positions.
650% more call options, than puts
Call options by funds: $2.73M | Put options by funds: $364K
35% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 63
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
17% more capital invested
Capital invested by funds: $1.01B → $1.18B (+$173M)
1% more funds holding
Funds holding: 223 → 226 (+3)
0.54% more ownership
Funds ownership: 92.84% → 93.39% (+0.54%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$11M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$10.3M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$8.15M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$5.72M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$22.6M |
| 2 |
Millennium Management
New York
|
-$8.12M |
| 3 |
Morgan Stanley
New York
|
-$6.12M |
| 4 |
BlackRock
New York
|
-$5.34M |
| 5 |
SIG
Senator Investment Group
New York
|
-$4.41M |
ADPT Hedge Fund Activity: Q1 2023 in Review
226 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q1 2023, worth a combined $1.18B — up 17% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ADPT positions and 22 closed out — a net gain of 4 holders — while 85 added to existing stakes and 63 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $11M. The largest seller was Bellevue Group, exiting entirely with an estimated $22.6M sold.
- 226 institutional investors held Adaptive Biotechnologies (ADPT) as of Q1 2023, up from 223 in Q4 2022.
- Funds reported $1.18B of Adaptive Biotechnologies stock for Q1 2023, up 17% quarter-over-quarter.
- 26 funds opened new Adaptive Biotechnologies positions in Q1 2023 and 22 closed out, a net change of +4 holders.
- The largest Adaptive Biotechnologies buyer in Q1 2023 was Pictet Asset Management (Switzerland), an estimated $11M added.
- The largest Adaptive Biotechnologies seller in Q1 2023 was Bellevue Group, an estimated $22.6M sold.
Based on aggregated 13F filings for Q1 2023.